Early research (Phase 1)Study completedNCT03000257What this trial is testingBudigalimab (ABBV-181) in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumors AbbVie 182
Testing effectiveness (Phase 2)Study completedNCT00333502What this trial is testingStudy of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsWho this might be right forCancerSolid Tumor NewLink Genetics Corporation 62
Early research (Phase 1)Study completedNCT00161187What this trial is testingIrradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid TumorWho this might be right forCancer University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Study completedNCT03037385What this trial is testingPhase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsWho this might be right forRET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more Hoffmann-La Roche 590
Early research (Phase 1)Active Not RecruitingNCT04975152What this trial is testingNeoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaWho this might be right forMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma H. Lee Moffitt Cancer Center and Research Institute 36
Testing effectiveness (Phase 2)Looking for participantsNCT06393816What this trial is testingFIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumWho this might be right forLarge Cell Neuroendocrine Carcinoma of the Lung Centre Leon Berard 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081What this trial is testingSelpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationWho this might be right forSolid TumorMedullary Thyroid Cancer Eli Lilly and Company 77
Testing effectiveness (Phase 2)Looking for participantsNCT06953089What this trial is testingDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsWho this might be right forSolid Tumors DualityBio Inc. 492
Testing effectiveness (Phase 2)Looking for participantsNCT07371663What this trial is testingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsWho this might be right forSolid CancersNSCLC (Advanced Non-small Cell Lung Cancer)Gastric (Stomach) Cancer+2 more Beijing Tide Pharmaceutical Co., Ltd 266
Testing effectiveness (Phase 2)Study completedNCT02114658What this trial is testingSorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsWho this might be right forThyroid Carcinoma Bayer 18
Early research (Phase 1)Looking for participantsNCT06021626What this trial is testingCRD3874-SI in People With Solid TumorsWho this might be right forSarcomaMerkel Cell Carcinoma Memorial Sloan Kettering Cancer Center 72
Early research (Phase 1)WithdrawnNCT06626256What this trial is testingSTIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWho this might be right forLocally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid Neoplasm+24 more City of Hope Medical Center
Early research (Phase 1)Study completedNCT00804336What this trial is testingPasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorCarcinoid TumorPancreatic Neuroendocrine Tumor Dana-Farber Cancer Institute 22
Testing effectiveness (Phase 2)Looking for participantsNCT05086692What this trial is testingA Beta-only IL-2 ImmunoTherapY StudyWho this might be right forAdvanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199272What this trial is testingA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesWho this might be right forSolid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more 23andMe, Inc. 141
Early research (Phase 1)Study completedNCT03538028What this trial is testingA Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesWho this might be right forCervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+14 more Incyte Biosciences International Sàrl 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04140526What this trial is testingSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCWho this might be right forNon Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more OncoC4, Inc. 733
Testing effectiveness (Phase 2)Study completedNCT01134250What this trial is testingCombination Therapy of F16IL2 and Paclitaxel in Solid Tumour PatientsWho this might be right forSolid TumorBreast CancerMetastatic Melanoma+1 more Philogen S.p.A. 48
Testing effectiveness (Phase 2)Study completedNCT02697591What this trial is testingINCAGN01876 in Participants With Advanced or Metastatic Solid TumorsWho this might be right forAdvanced MalignanciesMetastatic Cancer Incyte Biosciences International Sàrl 100
Not applicableStudy completedNCT00477919What this trial is testingE-MOSAIC Electronic Tool to Monitor SymptomsWho this might be right forCancer Swiss Cancer Institute 264